We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
DHR to Acquire Life Sciences Instrumentation Businesses from MDS Inc. and Life Technologies Corp
News

DHR to Acquire Life Sciences Instrumentation Businesses from MDS Inc. and Life Technologies Corp

DHR to Acquire Life Sciences Instrumentation Businesses from MDS Inc. and Life Technologies Corp
News

DHR to Acquire Life Sciences Instrumentation Businesses from MDS Inc. and Life Technologies Corp

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "DHR to Acquire Life Sciences Instrumentation Businesses from MDS Inc. and Life Technologies Corp"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Danaher Corporation has announced that it has signed a definitive agreement with MDS Inc. to acquire the Analytical Technologies division of MDS, which includes a 50% ownership position in Applied Biosystems/MDS Sciex joint venture (AB SCIEX), a mass spectrometry business, and a 100% ownership position in the former Molecular Devices Corporation, a bioresearch and analytical instrumentation company.

In a separate, but related transaction, Danaher also announced that it has signed a definitive agreement with Life Technologies Corporation to acquire the remaining 50% ownership position in AB SCIEX. After completion of both transactions, Danaher will own outright AB SCIEX and Molecular Devices. The aggregate purchase price for the combined transactions is $1.1 billion, including debt assumed and net of cash acquired.

Typical applications include proteomics research, drug development, food and environmental safety testing and diagnostics testing. Customers include academic and research institutions, pharmaceutical development labs primarily supporting clinical trials, testing and reference labs and hospitals. Molecular Devices supplies high-performance bio-analytical instrumentation systems and consumables that accelerate and improve research productivity and effectiveness in life science research and drug discovery.

The acquired businesses will operate within Danaher’s Medical Technologies segment, joining Danaher’s Leica, Radiometer, Sybron, and KaVo businesses, and will expand the segment’s annual revenues by more than $650 million. The acquired businesses will increase Danaher’s life sciences and diagnostics annual revenues to more than $2 billion.
Advertisement